Indian pharma resilient to US tariffs; Eyes US pricing reform gains: Ind-Ra
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
The projected business potential is around US$ 1 million in the first year
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
Subscribe To Our Newsletter & Stay Updated